Scarica l'app Stockscreener
2.4344
4.94%
0.1044
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Worthington Steel Posts Downbeat Earnings, Joins MillerKnoll And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
If You Invested $1,000 in Allogene Therapeutics (ALLO) - Stock Titan
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 9.2%Here's Why - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 11.4%Time to Buy? - MarketBeat
Piper Sandler analysts bullish on Allogene Therapeutics (ALLO) ahead of key ALPHA3 data readout - MSN
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Allogene targets pivotal ALPHA3 data in April and extends cash runway into 2028 while prioritizing scalable CAR T programs - MSN
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout - Insider Monkey
Allogene Therapeutics (NASDAQ:ALLO) SVP Sells $11,942.45 in Stock - MarketBeat
David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock - MarketBeat
Allogene (NASDAQ: ALLO) SVP share sale funds tax withholding - Stock Titan
Allogene (ALLO) CEO executes 47,763-share tax sell-to-cover transaction - Stock Titan
Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329 - Traders Union
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 5.1%Time to Sell? - MarketBeat
Take the Zacks approach to beat the markets: Starbucks, Amgen, Allogene in focus - MSN
Form 144 Allogene Therapeutics For: 16 March By Investing.com - Investing.com Australia
Allogene Therapeutics (NASDAQ: ALLO) proposes sale of 4,835 shares - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) RSUs Vest, 47,763 Common Shares - Stock Titan
Citizens reiterates Allogene stock rating on pipeline progress - Investing.com
Citizens reiterates Allogene stock rating on pipeline progress By Investing.com - Investing.com UK
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expands By 19.8% - MarketBeat
Allogene Therapeutics Banks on 2026 Trial Catalysts - The Globe and Mail
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Sahm
Analysts Are Bullish on Top Healthcare Stocks: Equillium (EQ), Qiagen (QGEN) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Canaccord Genuity Group Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics posts narrower-than-expected loss in Q4 - MSN
Canaccord Genuity Maintains Buy Rating for ALLO with $14 Target - GuruFocus
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - AOL.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - The Globe and Mail
Allogene Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Q32 Bio (QTTB) - The Globe and Mail
Allogene Therapeutics (ALLO) Projects Key Milestones for 2026 - GuruFocus
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - Sahm
Allogene Therapeutics 2025 Annual Report: Advancing Allogeneic CAR T Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlight - GuruFocus
Allogene Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast By Investing.com - Investing.com India
Allogene (ALLO) Q4 2025 Earnings Call Transcript - AOL.com
Rate Cut: Will Allogene Therapeutics Inc benefit from geopolitical trends2026 Drop Watch & Weekly Momentum Picks - baoquankhu1.vn
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):